[go: up one dir, main page]

PL1620058T3 - Kompozycja do poprawy funkcji poznawczych i pamięci - Google Patents

Kompozycja do poprawy funkcji poznawczych i pamięci

Info

Publication number
PL1620058T3
PL1620058T3 PL04727667T PL04727667T PL1620058T3 PL 1620058 T3 PL1620058 T3 PL 1620058T3 PL 04727667 T PL04727667 T PL 04727667T PL 04727667 T PL04727667 T PL 04727667T PL 1620058 T3 PL1620058 T3 PL 1620058T3
Authority
PL
Poland
Prior art keywords
memory
composition
improving cognition
cognition
improving
Prior art date
Application number
PL04727667T
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of PL1620058T3 publication Critical patent/PL1620058T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04727667T 2003-04-29 2004-04-15 Kompozycja do poprawy funkcji poznawczych i pamięci PL1620058T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment
EP04727667A EP1620058B1 (en) 2003-04-29 2004-04-15 Composition for improving cognition and memory
PCT/IL2004/000330 WO2004096118A2 (en) 2003-04-29 2004-04-15 Composition for improving cognition and memory

Publications (1)

Publication Number Publication Date
PL1620058T3 true PL1620058T3 (pl) 2012-07-31

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04727667T PL1620058T3 (pl) 2003-04-29 2004-04-15 Kompozycja do poprawy funkcji poznawczych i pamięci

Country Status (28)

Country Link
US (2) US8859593B2 (pl)
EP (1) EP1620058B1 (pl)
JP (2) JP4981440B2 (pl)
KR (1) KR101136885B1 (pl)
CN (1) CN1787820B (pl)
AR (1) AR048370A1 (pl)
AT (1) ATE539746T1 (pl)
BR (1) BRPI0409935A (pl)
CA (1) CA2521182C (pl)
CL (1) CL2004000877A1 (pl)
CY (1) CY1112689T1 (pl)
DK (1) DK1620058T3 (pl)
EA (1) EA008768B1 (pl)
ES (1) ES2380364T3 (pl)
IL (1) IL155666A (pl)
IS (1) IS8090A (pl)
MX (1) MXPA05011590A (pl)
NO (1) NO333015B1 (pl)
NZ (1) NZ542724A (pl)
PE (1) PE20050144A1 (pl)
PL (1) PL1620058T3 (pl)
PT (1) PT1620058E (pl)
SI (1) SI1620058T1 (pl)
TW (1) TWI340037B (pl)
UA (1) UA87980C2 (pl)
UY (1) UY28296A1 (pl)
WO (1) WO2004096118A2 (pl)
ZA (1) ZA200509508B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
BRPI0811052A2 (pt) 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
JP2015509106A (ja) 2012-01-26 2015-03-26 ヴァンダ ファーマシューティカルズ インコーポレイテッ 概日リズム障害の治療
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102148990B1 (ko) * 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
KR102361801B1 (ko) * 2015-02-04 2022-02-10 쏘 요세파 메넨데즈 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
MX386987B (es) 2016-10-31 2025-03-19 Neurim Pharma 1991 Mini-tabletas de melatonina y métodos de fabricación de las mismas.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) * 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
ES2028074T3 (es) 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
DE3645036A1 (de) 1986-11-18 1989-01-05 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
MX9205981A (es) * 1991-10-18 1993-04-01 Alza Corp Administracion transdermica de melatonina.
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
DE69303919T2 (de) * 1992-04-07 1997-01-30 Neurim Pharma 1991 Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
JPH09505028A (ja) * 1993-07-09 1997-05-20 シグナス，インコーポレイテッド 経皮的／経頬的にニコチン置換治療を提供する方法およびデバイス
JPH09512006A (ja) * 1994-04-13 1997-12-02 チバ−ガイギー アクチェンゲゼルシャフト 時間的に調節された薬物供給システム
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
JP4516159B2 (ja) 1995-02-01 2010-08-04 ニューリム ファーマシューティカルズ（１９９１）リミテッド 薬物嗜癖患者の治療のためのメラトニンの使用
US5696115A (en) 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
CZ298212B6 (cs) 1996-05-13 2007-07-25 Novartis Consumer Health S. A. Pomalu se rozpadající pastilka
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
ATE254618T1 (de) 1997-05-30 2003-12-15 Neurosearch As Spiro chinuclidin-derivate, ihre herstellung und verwendung
US6274615B1 (en) * 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US6353015B1 (en) 1998-08-26 2002-03-05 St. Elizabeth's Medical Center Method of treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
PL196413B1 (pl) 1999-02-05 2007-12-31 Cipla Ltd Kompozycja lecznicza, dozownik zawierający kompozycję leczniczą, sposób przygotowania dozownika i zastosowanie kompozycji
US6353051B1 (en) * 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
HK1052655A1 (zh) 2000-01-05 2003-09-26 纽里姆药品(1991)有限公司 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑
EP2140868A1 (en) * 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2001282873A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AR033444A1 (es) 2001-03-26 2003-12-17 Smithkline Beecham Corp Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
EP1304048B1 (en) 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
US7113651B2 (en) * 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
WO2004096118B1 (en) 2005-12-01
US8859593B2 (en) 2014-10-14
CN1787820B (zh) 2010-05-05
JP2006525317A (ja) 2006-11-09
BRPI0409935A (pt) 2006-04-25
IL155666A0 (en) 2004-09-27
WO2004096118A3 (en) 2005-10-13
KR101136885B1 (ko) 2012-04-20
CA2521182C (en) 2011-05-31
CY1112689T1 (el) 2016-02-10
JP2012116859A (ja) 2012-06-21
PT1620058E (pt) 2012-04-13
IL155666A (en) 2013-12-31
EP1620058B1 (en) 2012-01-04
US20140378512A1 (en) 2014-12-25
NO20055531L (no) 2005-11-23
NO333015B1 (no) 2013-02-18
TW200501948A (en) 2005-01-16
KR20060005402A (ko) 2006-01-17
EA200501666A1 (ru) 2006-06-30
CN1787820A (zh) 2006-06-14
HK1087635A1 (zh) 2006-10-20
IS8090A (is) 2005-10-25
AR048370A1 (es) 2006-04-26
UA87980C2 (ru) 2009-09-10
EA008768B1 (ru) 2007-08-31
ES2380364T3 (es) 2012-05-11
CL2004000877A1 (es) 2005-01-07
ZA200509508B (en) 2006-11-29
WO2004096118A2 (en) 2004-11-11
US20060229340A1 (en) 2006-10-12
EP1620058A4 (en) 2006-07-26
UY28296A1 (es) 2004-11-30
EP1620058A2 (en) 2006-02-01
JP4981440B2 (ja) 2012-07-18
ATE539746T1 (de) 2012-01-15
PE20050144A1 (es) 2005-05-12
CA2521182A1 (en) 2004-11-11
TWI340037B (en) 2011-04-11
NZ542724A (en) 2007-05-31
DK1620058T3 (da) 2012-05-07
MXPA05011590A (es) 2006-03-08
SI1620058T1 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
AU2003256805A8 (en) Compounds compositions and methods
TWI340037B (en) Composition for improving cognition and memory
GB0203421D0 (en) Composition
EP1684771A4 (en) COMPOSITION AND METHOD
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB0218241D0 (en) Composition
EP1495751A4 (en) hair dye
GB0213767D0 (en) Composition
GB0203528D0 (en) Process and composition
GB0203616D0 (en) Composition
GB0303581D0 (en) Process and composition
GB0325237D0 (en) Composition and use
GB0301401D0 (en) Composition and use
GB0325239D0 (en) Composition and use
GB0325238D0 (en) Composition and use
GB0311167D0 (en) Composition and use
GB0311166D0 (en) Composition and use
GB0311164D0 (en) Composition and use
GB0326699D0 (en) Method and composition